ReviewCureus2021
A Paradigm Shift in the Management of Atherosclerosis: Protective Role of Sirtuins in Atherosclerosis.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Can Sirtuin 1 Serve as a Therapeutic Target in Pulmonary Arterial Hypertension? A Comprehensive Review.Molecules (Basel, Switzerland) · 2025Review
- Role of sirtuins in attenuating plaque vulnerability in atherosclerosis.Molecular and cellular biochemistry · 2024Review
- Incidence of microvascular dysfunction is increased in hyperlipidemic mice, reducing cerebral blood flow and impairing remote memory.Frontiers in endocrinology · 2024Article
- SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells.Theranostics · 2023Article
- Association of Sirtuin Gene Polymorphisms with Susceptibility to Coronary Artery Disease in a North Chinese Population.BioMed research international · 2022Article
- Potential Role of Lisinopril in Reducing Atherosclerotic Risk: Evidence of an Antioxidant Effect in Human Cardiomyocytes Cell Line.Frontiers in pharmacology · 2022Article
- Investigation of miRNA-199a-5p Expression and its Clinical Association With LDL Cholesterol Levels in Atherosclerosis.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Facing the rise of an aging population and age-related pathologies such as atherosclerosis will continue to be some of the biggest challenges encountering health care. Regardless of considerable advancements in management and prevention to deal with atherosclerosis and other related pathologies. The current guidelines for preventing and managing atherosclerotic diseases are lifestyle changes, blood pressure control, blood glucose control, and lipid control. There has been an increase in pre-clinical studies regarding the effects of sirtuins on atherosclerosis and this review aims to highlight the benefits of sirtuins in atherosclerosis. We did an extensive search using the PubMed database with the medical subject headings (MeSH) keywords "sirtuin'' and "atherosclerosis." The reviewed literature reported that sirtuins prevent and ameliorate atherosclerosis by halting inflammation, apoptosis, oxidative stress, and regulating low-density lipoprotein (LDL) cholesterol. Sirtuin 1 (SIRT1) and sirtuin 6 (SIRT6) inhibit the RELA component of NF-kB, thus suppressing inflammation, SIRT1 inhibits p53 by deacetylation, and the latter stabilize telomeres thus preventing apoptosis and cell death. Sirtuin 3 (SIRT3) inhibits oxidative stress by driving the production of reduced glutathione. Sirtuin 2 (SIRT2) regulates LDL cholesterol by inhibiting pcsk9, increasing LDL receptors on the cell surface of hepatocytes. A combination of these effects of sirtuins in the endothelial cells suggests sirtuins are anti-atherogenic and could revolutionize the standards for the management of atherosclerosis. This article also emphasizes the need for future research on human cells or subjects rather than animal subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.